Lopinavir: Difference between revisions
David Canner (talk | contribs) New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Lopinavir, better known as Kaletra, (1hsg)"/> ===Better Known as: Kaletra=== * Marketed B... |
David Canner (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Lopinavir, better known as Kaletra, ([[ | <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Lopinavir, better known as Kaletra, ([[2q5k]])"/> | ||
===Better Known as: Kaletra=== | ===Better Known as: Kaletra=== | ||
* Marketed By: Abbott<br /> | * Marketed By: Abbott<br /> | ||
| Line 5: | Line 5: | ||
* Drug Class: [[HIV Protease]] Inhibitor | * Drug Class: [[HIV Protease]] Inhibitor | ||
* Date of FDA Approval (Patent Expiration): 2000 (2016) <br /> | * Date of FDA Approval (Patent Expiration): 2000 (2016) <br /> | ||
* | * 2007 Sales: $1.1 Billion | ||
* Importance: Forms part of the Lopinavir & Ritonavir first-line therapy for HIV infections. Due to its low bioavilbility, it is sold as a co-formulation with [[Ritonavir]], which is a potent CYP3A4 inhibitor. | * Importance: Forms part of the Lopinavir & Ritonavir first-line therapy for HIV infections. Due to its low bioavilbility, it is sold as a co-formulation with [[Ritonavir]], which is a potent CYP3A4 inhibitor. | ||
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | ||